DEPLOYDatabase

Robot model

Evie Ring (and EvieMED)

Movano Health (NASDAQ: MOVE; led by chief executive John Mastrototaro) makes the women's-health-focused Evie smart ring, recorded in the biometric form factor,…

Track Evie Ring (and EvieMED)
Manufacturer
Movano Health
Form factor
biometric
Maturity
commercial
Lifecycle
paused
Deployments
1

pausedPaused. Operational suspension reported by the operator or manufacturer.

Overview

Movano Health (NASDAQ: MOVE; led by chief executive John Mastrototaro) makes the women's-health-focused Evie smart ring, recorded in the biometric form factor, with cycle tracking and women's-health metrics as its editorial differentiator. A load-bearing entity split applies: there are two rings, the consumer Evie Ring, which tracks the menstrual cycle, sleep, energy, heart rate, blood oxygen, and mood as a general-wellness device that is not FDA-cleared, and the separate business-to-business EvieMED Ring, which received an FDA 510(k) clearance for its pulse oximeter and heart rate on December 2, 2024 for clinical trials, remote patient monitoring, and payor and pharma use, with a pivotal study showing accuracy across darker skin tones, so the clearance must not be attributed to the consumer Evie Ring. A significant financial cap-flag is the real risk here: Movano is distressed, with its SEC filings showing going-concern substantial doubt, an accumulated deficit of $160.5 million as of September 30, 2025, cash not sufficient to fund operations beyond the first quarter of 2026 without further capital or a merger, a strategic review and possible sale underway, a one-for-ten reverse stock split in October 2025 to regain NASDAQ compliance, and a $1.5 million bridge loan at an effective rate around 111.6 percent secured by the company's intellectual property that transfers to the lender if a merger fails to close, so the registry records it at commercial maturity but at risk with an active lifecycle and a re-verification flag given the volatile status. A source-drift note: a secondary article cites a stale 2024 cash figure that the SEC filings supersede with the going-concern position, and the company's market-size framing is total-addressable-market language rather than verified revenue.

Verified vs. claimed

Maturity stage
commercial(Commercially deployed with revenue-generating operations.)
Verified deployments
1 deployment on file
Sources on file
5 sources, view all

Key facts

Form factor

Biometric smart ring

FDA clearance

FDA 510(k) cleared for pulse oximeter and heart rate (K232667, December 2, 2024) - EvieMED Ring only

Accumulated deficit

$160.5 million as of September 30, 2025

Bridge loan

$1.5 million at approximately 111.6% effective rate, secured by company IP

Reverse stock split

1-for-10 reverse split in October 2025 to regain NASDAQ compliance

Specs

Notes

Verified (women's-health differentiator + the two-ring split): Movano Health (NASDAQ: MOVE; CEO John Mastrototaro) makes the women's-health-focused Evie Ring - the editorial differentiator (cycle tracking + women's-health metrics as primary positioning). KEY split: the consumer Evie Ring is GENERAL-WELLNESS (not cleared); the FDA 510(k) clearance (pulse oximeter + HR, Dec 2 2024) belongs to the separate B2B EvieMED Ring - do NOT attribute the clearance to the consumer Evie. A pivotal study showed accuracy across darker skin tones (Fitzpatrick)., FINANCIAL CAP-FLAG (going-concern - the real risk): Movano is financially DISTRESSED: SEC 10-Qs show going-concern substantial doubt, accumulated deficit $160.5M (Sep 30 2025), cash not sufficient beyond Q1 2026 without further capital or a merger; a strategic review / possible sale is underway; a 1-for-10 reverse split (Oct 2025) to regain NASDAQ compliance; a $1.5M bridge loan at ~111.6% effective rate secured by Movano's IP (transfers to the lender if a merger fails). maturity=commercial but AT-RISK; lifecycleState=active. RE-VERIFY before relying on (status volatile)., Cap-flag (source drift): A reverse-split secondary source cites a STALE Q3-2024 cash figure ($11.3M / '12 months runway') - the SEC 10-Qs SUPERSEDE it (going-concern, runway not beyond Q1 2026). Trust the 10-Q. '$40B market' framing is company TAM, not verified revenue., Re-verify 2026-06-03 (MATERIAL): Movano Health's strategic review resolved in a COMPLETED all-stock reverse merger with Corvex (closed Mar 19 2026; renamed Corvex, Inc. effective Mar 23 2026; same ticker NASDAQ: MOVE). The combined entity pivoted to AI cloud / GPU infrastructure (NVIDIA H200); legacy Movano shareholders retained <5%. Evie / Wellness Ring CONSUMER SALES are PAUSED and the healthcare assets (incl. the FDA-cleared EvieMED Ring) are being explored for sale/divestiture. A 1-for-10 reverse split occurred (~Oct 2025). lifecycleState active->PAUSED (sales paused, divestiture-pending; maturityStage left at commercial as the historical peak, per the active/retired split). Cap-flag: the divestiture is an INTENTION, not a closed transaction; a '$1B equity facility' and co-CEO appointments are conditional/reported-only.

Specs

TWO rings: Evie Ring (CONSUMER, women's-health-focused: menstrual-cycle tracking, sleep, energy, HR, SpO2, mood/goal trends; GENERAL-WELLNESS) + EvieMED Ring (B2B/clinical variant; FDA 510(k)-cleared pulse oximeter + HR, Dec 2 2024; for clinical trials / remote patient monitoring / payors-pharma). Company: Movano Health (NASDAQ: MOVE; CEO John Mastrototaro).

Form Factor

biometric (biometric-primary women's-health smart ring + AI; consumer general-wellness + B2B FDA-cleared variant)

Fda clearance

Source: fda.gov Status: cleared; Details: FDA-cleared for blood oxygen, skin temperature, heart rate (K232667, 2024). EvieMED = clinical version. De Novo pathway for novel ring form factor.; Audited at: 2026-06-07; Source name: FDA; Health claim: Women's health-focused metrics (menstrual cycle correlation, sleep, activity). FDA-cleared subset; wellness positioning for consumer version.; Verification posture: verified

Data & sources

Company filings

1

Press releases

2

Web sources

2

5 sources backing this record.View all →

Availability and pricing

Availability
Paused
Price
Not publicly disclosed
Units in field
Not disclosed
Sales model
Not disclosed
Lead time
Not disclosed

Pricing

No verified price is on record for Evie Ring (and EvieMED). Physical-AI systems are often sold through enterprise contracts or operated as a service rather than at a public list price.

How DEPLOY tracks pricing

Deployments (1)

Evie Ring (and EvieMED) on the deployment map

Where Evie Ring (and EvieMED) is verified operating. Explore the deployment map by place and type.

Recent activity

Every change to this record is dated, sourced, and independently verified where marked.

Full change history →

Deployment-verified media (1)

PRIMARY SOURCE
Courtesy of Movano

Movano's introduction of the Evie Ring. The Evie Ring is a wellness device (heart rate, SpO2 spot checks, skin temperature, menstrual and symptom tracking), not an FDA-cleared medical device.

From deployment: United States

Safety record

No incidents on record for Evie Ring (and EvieMED).

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Sources (5)

  1. https://www.prnewswire.com/news-releases/movano-health-receives-fda-clearance-for-eviemed-ring-302319677.html
  2. https://www.mobihealthnews.com/news/movano-health-secures-fda-clearance-eviemed-ring
  3. https://www.sec.gov/Archives/edgar/data/0001734750/000121390025110877/ea0261389-10q_movano.htm
  4. https://www.corvex.ai/blog/press-release-corvex-to-go-public-in-all-stock-merger-withmovano-creating-a-pure-play-platform-for-secure-ai-infrastructure-and-high-performanceinference
  5. https://www.arlnow.com/2026/03/25/va-square-based-ai-company-goes-public-after-merger-with-health-tech-firm/

Compare Evie Ring (and EvieMED)

Common questions

What is Evie Ring (and EvieMED)?
Movano Health (NASDAQ: MOVE; led by chief executive John Mastrototaro) makes the women's-health-focused Evie smart ring, recorded in the biometric form factor, with cycle tracking and women's-health metrics as its editorial differentiator. A load-bearing entity split applies: there are two rings, the consumer Evie Ring, which tracks the menstrual cycle, sleep, energy, heart rate, blood oxygen, and mood as a general-wellness device that is not FDA-cleared, and the separate business-to-business EvieMED Ring, which received an FDA 510(k) clearance for its pulse oximeter and heart rate on December 2, 2024 for clinical trials, remote patient monitoring, and payor and pharma use, with a pivotal study showing accuracy across darker skin tones, so the clearance must not be attributed to the consumer Evie Ring. A significant financial cap-flag is the real risk here: Movano is distressed, with its SEC filings showing going-concern substantial doubt, an accumulated deficit of $160.5 million as of September 30, 2025, cash not sufficient to fund operations beyond the first quarter of 2026 without further capital or a merger, a strategic review and possible sale underway, a one-for-ten reverse stock split in October 2025 to regain NASDAQ compliance, and a $1.5 million bridge loan at an effective rate around 111.6 percent secured by the company's intellectual property that transfers to the lender if a merger fails to close, so the registry records it at commercial maturity but at risk with an active lifecycle and a re-verification flag given the volatile status. A source-drift note: a secondary article cites a stale 2024 cash figure that the SEC filings supersede with the going-concern position, and the company's market-size framing is total-addressable-market language rather than verified revenue.
How much does Evie Ring (and EvieMED) cost?
Evie Ring (and EvieMED)'s price is not publicly disclosed. DEPLOY has no verified price on record for Evie Ring (and EvieMED) from Movano Health. Physical-AI systems like this are often sold through enterprise contracts or operated as a service rather than at a public list price; check the manufacturer for the latest.
Is Evie Ring (and EvieMED) actually deployed in the real world?
Yes. Evie Ring (and EvieMED) is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.
Who makes Evie Ring (and EvieMED)?
Evie Ring (and EvieMED) is made by Movano Health, based in Pleasanton, California, USA, founded in 2018.
Where is Evie Ring (and EvieMED) deployed?
1 verified deployment of Evie Ring (and EvieMED) is on the DEPLOY registry, including at United States.
Methodology: Verified · 5 sources (3 primary) · last reviewed 2026-06-28

Verification posture

Verified

High confidence

Review state

Active watch · 4-6 weeks

Last reviewed 2026-06-28

lifecycle-paused-post-Corvex-merger

Maturity + lifecycle

Maturity stage: commercial

Lifecycle: paused

Architectural position

Cohort: biometric

Sources by quality tier

2
primary-company-ir
Company IR disclosure
2
unclassified
Unclassified source
1
primary-sec-filing
SEC filing

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for Evie Ring (and EvieMED).

Recent coverage

Evie Ring (and EvieMED) in third-party press

Movano Health secures FDA clearance for EvieMED Ring

Jun 15, 2026

FDA exempts more wearable AI features from oversight

Apr 15, 2026